The companies teamed up to design and eventually commercialize a proprietary, non-invasive, wearable CGM device. They aim to remove the technology and patient-care roadblocks that exist within continuous glucose monitoring.
Phillips-Medisize develops drug delivery, in vitro diagnostic and medtech devices. Finland-based GlucoModicum utilizes magnetohydrodynamic (MHD) technology to quickly and easily extract a glucose sample. This technology applies a small amount of energy directly to interstitial fluid to drive it to the surface of the skin.
The device utilizing this technology, called Talisman, adheres to a patient’s arm. It integrates MHD technology, ultra-sensitive biosensors and advanced algorithms while connecting t…